|
1
|
Russell RG: Bisphosphonates: The first 40
years. Bone. 49:2–19. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Coxon FP, Thompson K and Rogers MJ: Recent
advances in understanding the mechanism of action of
bisphosphonates. Curr Opin Pharmacol. 6:307–312. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Reyes C, Hitz M, Prieto-Alhambra D and
Abrahamsen B: Risks and benefits of bisphosphonate therapies. J
Cell Biochem. 117:20–28. 2016. View Article : Google Scholar
|
|
4
|
Watts N, Freedholm D and Daifotis A: The
clinical tolerability profile of alendronate. Int J Clin Pract
Suppl. 101:51–61. 1999.
|
|
5
|
Rubegni P and Fimiani M: Images in
clinical medicine. Bisphosphonate-associated contact stomatitis. N
Engl J Med. 355:e252006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
de Groen PC, Lubbe DF, Hirsch LJ, Daifotis
A, Stephenson W, Freedholm D, Pryor-Tillotson S, Seleznick MJ,
Pinkas H and Wang KK: Esophagitis associated with the use of
alendronate. N Engl J Med. 335:1016–1021. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Proksch E, Brandner JM and Jensen JM: The
skin: An indispensable barrier. Exp Dermatol. 17:1063–1072. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bae S, Sun S, Aghaloo T, Oh JE, McKenna
CE, Kang MK, Shin KH, Tetradis S, Park NH and Kim RH: Development
of oral osteomucosal tissue constructs in vitro and localization of
fluorescently-labeled bisphosphonates to hard and soft tissue. Int
J Mol Med. 34:559–563. 2014.PubMed/NCBI
|
|
9
|
Kim RH, Lee RS, Williams D, Bae S, Woo J,
Lieberman M, Oh JE, Dong Q, Shin KH, Kang MK, et al:
Bisphosphonates induce senescence in normal human oral
keratinocytes. J Dent Res. 90:810–816. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Green JR: Chemical and biological
prerequisites for novel bisphosphonate molecules: Results of
comparative preclinical studies. Semin Oncol. 28(Suppl 6): 4–10.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Iguchi T, Miyakawa Y, Yamamoto K, Kizaki M
and Ikeda Y: Nitrogen-containing bisphosphonates induce S-phase
cell cycle arrest and apoptosis of myeloma cells by activating MAPK
pathway and inhibiting mevalonate pathway. Cell Signal. 15:719–727.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Horiuchi K, Umetani M, Minami T, Okayama
H, Takada S, Yamamoto M, Aburatani H, Reid PC, Housman DE, Hamakubo
T, et al: Wilms' tumor 1-associating protein regulates G2/M
transition through stabilization of cyclin A2 mRNA. Proc Natl Acad
Sci USA. 103:17278–17283. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Henglein B, Chenivesse X, Wang J, Eick D
and Bréchot C: Structure and cell cycle-regulated transcription of
the human cyclin A gene. Proc Natl Acad Sci USA. 91:5490–5494.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Reszka AA and Rodan GA:
Nitrogen-containing bisphosphonate mechanism of action. Mini Rev
Med Chem. 4:711–719. 2004.PubMed/NCBI
|
|
15
|
Bergstrom JD, Bostedor RG, Masarachia PJ,
Reszka AA and Rodan G: Alendronate is a specific, nanomolar
inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys.
373:231–241. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
van Beek E, Pieterman E, Cohen L, Löwik C
and Papapoulos S: Nitrogen-containing bisphosphonates inhibit
isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase
activity with relative potencies corresponding to their
antiresorptive potencies in vitro and in vivo. Biochem Biophys Res
Commun. 255:491–494. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sinensky M: Recent advances in the study
of prenylated proteins. Biochim Biophys Acta. 1484:93–106. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Williams CL: The polybasic region of Ras
and Rho family small GTPases: A regulator of protein interactions
and membrane association and a site of nuclear localization signal
sequences. Cell Signal. 15:1071–1080. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Csépányi-Kömi R, Lévay M and Ligeti E:
Small G proteins and their regulators in cellular signalling. Mol
Cell Endocrinol. 353:10–20. 2012. View Article : Google Scholar
|
|
20
|
Teramoto H, Malek RL, Behbahani B,
Castellone MD, Lee NH and Gutkind JS: Identification of H-Ras,
RhoA, Rac1 and Cdc42 responsive genes. Oncogene. 22:2689–2697.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Coso OA, Chiariello M, Yu JC, Teramoto H,
Crespo P, Xu N, Miki T and Gutkind JS: The small GTP-binding
proteins Rac1 and Cdc42 regulate the activity of the JNK/SAPK
signaling pathway. Cell. 81:1137–1146. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hill CS, Wynne J and Treisman R: The Rho
family GTPases RhoA, Rac1, and CDC42Hs regulate transcriptional
activation by SRF. Cell. 81:1159–1170. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Okan E, Drewett V, Shaw PE and Jones P:
The small-GTPase RalA activates transcription of the urokinase
plasminogen activator receptor (uPAR) gene via an AP1-dependent
mechanism. Oncogene. 20:1816–1824. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mönkkönen H, Kuokkanen J, Holen I, Evans
A, Lefley DV, Jauhiainen M, Auriola S and Mönkkönen J:
Bisphosphonate-induced ATP analog formation and its effect on
inhibition of cancer cell growth. Anticancer Drugs. 19:391–399.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sonnemann J, Eckervogt V, Truckenbrod B,
Boos J, Winkelmann W and van Valen F: The bisphosphonate
pamidronate is a potent inhibitor of Ewing's sarcoma cell growth in
vitro. Anticancer Drugs. 14:767–771. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li YY, Chang JW, Liu YC, Wang CH, Chang
HJ, Tsai MC, Su SP and Yeh KY: Zoledronic acid induces cell-cycle
prolongation in murine lung cancer cells by perturbing cyclin and
Ras expression. Anticancer Drugs. 22:89–98. 2011. View Article : Google Scholar
|
|
27
|
Yam CH, Fung TK and Poon RY: Cyclin A in
cell cycle control and cancer. Cell Mol Life Sci. 59:1317–1326.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Iguchi T, Miyakawa Y, Saito K, Nakabayashi
C, Nakanishi M, Saya H, Ikeda Y and Kizaki M: Zoledronate-induced S
phase arrest and apoptosis accompanied by DNA damage and activation
of the ATM/Chk1/cdc25 pathway in human osteosarcoma cells. Int J
Oncol. 31:285–291. 2007.PubMed/NCBI
|
|
29
|
Ory B, Blanchard F, Battaglia S, Gouin F,
Rédini F and Heymann D: Zoledronic acid activates the DNA S-phase
checkpoint and induces osteosarcoma cell death characterized by
apoptosis-inducing factor and endonuclease-G translocation
independently of p53 and retinoblastoma status. Mol Pharmacol.
71:333–343. 2007. View Article : Google Scholar
|
